Involvement of the serotonin transporter in the formation of hydroxyl radicals induced by 3,4-methylenedioxymethamphetamine

European Journal of Pharmacology

Volumn 385, Issue 2-3, 1999, Pages 103-110

  Shankaran, Mahalakshmi ^a   Yamamoto, Bryan K ^b   Gudelsky, Gary A ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

5 HT (5 hydroxytryptamine, serotonin); Hydroxyl radical; MDMA (3,4 methylenedioxymethamphetamine); Neurotoxicity

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; DOPAMINE; FLUOXETINE; HYDROXYL RADICAL; SEROTONIN; SEROTONIN TRANSPORTER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MICRODIALYSIS; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT;

EID: 0032763755     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00728-1     Document Type: Article

References (51)

1. 1A receptor density and 8-OH-DPAT-induced hypothermia: blockade by drugs preventing 5-hydroxytryptamine depletion. Eur. J. Pharmacol. 346:1998;181-188.
2. Althaus J.S., Andrus P.K., Hall E.D., VonVoigtlander P.F. Improvements in salicylate trapping method for measurement of hydroxyl radical levels in the brain. Ohnishi S.T., Ohnishi T. Central nervous, system trauma: research techniques. 1995;437-444 CRC Press, Boca Raton, FL.
3. Battaglia G., Yeh S.Y., O'Hearn E., Molliver M.E., Kuhar M.J., DeSouza E.B. 3,4-methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H] paroxetine-labelled serotonin uptake sites. J. Pharmacol. Exp. Ther. 242:1987;911-916.
4. Bolla K.I., McCann U.D., Ricaurte G.A. Memory impairment in abstinent MDMA ("Ecstasy") users. Neurology. 51:1998;1532-1537.
5. Brodkin J., Mallaya A., Nash J.F. Effect of acute monoamine depletion on 3,4-methylenedioxymethamphetamine-induced toxicity. Pharmacol. Biochem. Behav. 45:1993;647-652.
6. Caccia S., Fracasso C., Garattini S., Guiso G., Sarati S. Effects of short- and long-term administration of fluoxetine on the monoamine content of rat brain. Neuropharmacology. 31:1992;343-347.
7. Cadet J.L., Brannock C. Free radicals and the pathobiology of dopamine systems. Neurochem. Int. 32:1998;117-131.
8. Cadet J.L., Ladenheim B., Hirata H., Rothman R.B., Ali S., Carlson E., Epstein C., Moran T.H. Superoxide radicals mediate the biochemical effects of methylenedioxymethamphetamine (MDMA): evidence from using CuZn-superoxide dismutase transgenic mice. Synapse. 21:1995;169-176.
9. Cohen G. Monoamine oxidase, hydrogen peroxide, and Parkinson's disease. Adv. Neurol. 45:1987;119-125.
10. Colado M.I., Green A.R. The spin trap reagent α-phenyl-N-tert-butyl nitrone prevents 'ecstasy'-induced neurodegeneration of 5-hydroxytryptamine neurons. Eur. J. Pharmacol. 280:1995;343-346.
11. Colado M.I., Williams J.L., Green A.R. The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4-methylenedioxyamphetamine (MDA) in the dark agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Br. J. Pharmacol. 115:1995;1281-1289.
12. Colado M.I., O'Shea E., Granados R., Murray T.K., Green A.R. In vivo evidence for free radical involvement in the degeneration of rat brain 5-HT following administration of MDMA (ecstasy) and p-choroamphetamine but not the degeneration following fenfluramine. Br. J. Pharmacol. 121:1997;889-900.
13. Colado M.I., O'Shea E., Esteban B., Granados R., Green A.R. In vivo evidence against clomethiazole being neuroprotective against MDMA ('ecstasy')-induced degeneration of rat brain 5-HT nerve terminals by a free radical scavenging mechanism. Neuropharmacology. 38:1999;307-314.
14. Colado M.I., O'Shea E., Granados R., Esteban B., Martin A.B., Green A.R. Studies on the role of dopamine in the degeneration of 5-HT nerve endings in the brain of dark agouti rats following 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy') administration. Br. J. Pharmacol. 126:1999;911-924.
15. De Vito M.J., Wagner G.C. Methamphetamine-induced neuronal damage: a possible role for free radicals. Neuropharmacology. 28:1989;1145-1150.
16. Faraj B.A., Olkowski Z.L., Jackson R.T. Active [3H]-dopamine uptake by human lymphocytes: correlates with serotonin transporter activity. Pharmacology. 48:1994;320-327.
17. Fleckenstein A.E., Wilkins D.G., Gibb J.W., Hanson G.R. Interaction between hyperthermia and oxygen radical formation in the 5-hydroxytryptaminergic response to a single methamphetamine administration. J. Pharmacol. Exp. Ther. 283:1997;281-285.
18. Floyd R.A., Watson J.J., Wong P.K. Sensitive assay of hydroxyl radical formation utilizing high pressure liquid chomatography with electrochemical detection of phenol and salicylate hydroxylation products. J. Biochem. Biophys. Methods. 10:1984;221-235.
19. Gardier A.M., Lepoul E., Trouvin J.H., Chanut E., Dessalles M.C., Jacquot C. Changes in dopamine metabolism in rat forebrain regions after cessation of long-term fluoxetine treatment: relationship with brain concentrations of fluoxetine and norfluoxetine. Life Sci. 54:1993;PL51-PL56.
20. Gibb J., Johnson M., Hanson G. Neurochemical basis of neurotoxicity. Neurotoxicology. 11:1990;317-321.
21. Graham D.G. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol. 14:1978;644-653.
22. Green A.R., Cross A.J., Goodwin G.M. Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or Ecstasy). Psychopharmacology. 119:1995;247-260.
23. Gudelsky G.A. Effect of ascorbate and cysteine on the 3,4-methylenedioxymethamphetamine-induced depletion of brain serotonin. J. Neural Transm. 103:1996;1397-1404.
24. Gudelsky G.A., Nash J.F. Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions. J. Neurochem. 66:1996;243-249.
25. Gudelsky G.A., Yamamoto B.K. MDMA increases the extracellular concentration of 2,3-dihydroxybenzoic acid in the striatum: evidence for increased hydroxyl radical formation. Abs. Soc. Neurosci. 20:1994;1026.
26. Gudelsky G.A., Yamamoto B.K., Nash J.F. Potentiation of 3,4-methylenedioxymethamphetamine-induced dopamine release and serotonin neurotoxicity by 5-HT2 agonists. Eur. J. Pharmacol. 264:1994;325-330.
27. Hiramatsu M., Kumagai Y., Unger S.E., Cho A.K. Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct. J. Pharmacol. Exp. Ther. 254:1990;521-527.
28. Huang N.-K., Wan F.-J., Tseng C.-J., Tung C.-S. Amphetamine induces hydroxyl radical formation in the striatum of rats. Life Sci. 22:1997;2219-2229.
29. Johnson M.P., Nichols D.E. Combined administration of a non-neurotoxic 3,4-methylenedioxymethamphetamine analogue with amphetamine produces serotonin neurotoxicity in rats. Neuropharmacology. 30(7):1991;819-822.
30. Malagie I., Trillat A.-C., Douvier E., Anmella M.-C. Regional differences in the effect of the combined treatment of WAY 100635 and fluoxetine: an in vivo microdialysis study. Naunyn-Schmiedeberg's Arch. Pharmacol. 354:1996;785-790.
31. Malberg J., Sabol K.E., Seiden L.S. Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat. J. Pharmacol. Exp. Ther. 278:1996;258-267.
32. O'Hearn E., Battaglia G., De Souza E.B., Kuhar M.J., Molliver M.E. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J. Neurosci. 8(8):1988;2788-2803.
33. Paxinos G., Watson C. The rat brain in stereotaxic coordinates. 1986;Academic Press, Orlando.
34. Scallet A.C., Lipe G.W., Ali S.F., Holson R.R., Frith C.H., Slikker W. Jr. Neuropathological evaluation by combined immunohistochemistry and degeneration-specific methods: application to methylenedioxymethamphetamine. Neurotoxicology. 9:1988;529-538.
35. Schmidt C.J. Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J. Pharmacol. Exp. Ther. 240:1987;1-7.
36. Schmidt C.J., Kehne J.H. Neurotoxicity of MDMA: neurochemical effects. Ann. NY Acad. Sci. 600:1990;665-681.
37. Schmidt C.J., Lovenberg W. In vitro demonstration of dopamine uptake by neostriatal serotonergic neurons in the rat. Neuroscience. 59:1985;9-14.
38. Schmidt C.J., Taylor V.L. Depression of rat brain tryptophan hydroxylase activity following the acute administration of methylenedioxymethamphetamine. Biochem. Pharmacol. 36(23):1987;4095-5102.
39. Shankaran M., Gudelsky G.A. Effect of 3,4-methylenedioxymethamphetamine (MDMA) on hippocampal dopamine and serotonin. Pharmacol. Biochem. Behav. 61:1998;361-366.
40. Shankaran M., Yamamoto B.K., Gudelsky G.A. Mazindol attenuates the 3,4-methylenedioxymethamphetamine-induced formation of hydroxyl radicals and long-term depletion of serotonin in the striatum. J. Neurochem. 72:1999;2516-2522.
41. Sprague J., Nichols D.E. The monoamine oxidase-B inhibitor l-deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficits. J. Pharmacol. Exp. Ther. 273:1995;667-673.
42. Sprague J.E., Everman S.L., Nichols D.E. An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. Neurotoxicology. 19:1998;427-442.
43. Ste-Marie L., Boismenu D., Vachon L., Montgomery J. Evaluation of sodium 4-hydroxybenzoate as an hydroxyl radical trap using gas chomatography-mass spectrometry and high-performance liquid chomatography with electrochemical detection. Anal. Biochem. 241:1996;67-74.
44. Steranka L.R., Rhind A.W. Effect of cysteine on the persistent depletion of brain monoamines by amphetamine, p-chloroamphetamine and MPTP. Eur. J. Pharmacol. 133:1987;191-197.
45. Stone D.M., Stahl D., Hanson G.R., Gibb J.W. The effects of 3,4-methylenedioxymethamphetamine (MDMA) on monoaminergic systems in rat brain. Eur. J. Pharmacol. 128:1986;41-49.
46. Stone D.M., Merchant K.M., Hanson G.R., Gibb J.W. Immediate and long-term effects of 3,4-methylenedioxymethamphetamine on serotonin pathways in brain of rat. Neuropharmacology. 26(12):1987;1677-1683.
47. Stone D.M., Hanson G.R., Gibb J.W. In vitro reactivation of rat cortical tryptophan hydroxylase following in vivo inactivation by methylenedioxymethamphetamine. J. Neurochem. 53:1988;572-581.
48. Stone D.M., Johnson M., Hanson G.R., Gibb J.W. Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine. J. Pharmacol. Exp. Ther. 128:1988;79-87.
49. Wong K.-S., Goyal R.N., Wrona M.Z., Blank C.L., Dryhurst G. 7-S-Glutathionyl-tryptamine-4,5-dione: a possible aberrant metabolite of serotonin. Biochem. Pharmacol. 46:1993;1637-1652.
50. Wrona M.Z., Dryhurst G. Oxidation of serotonin by superoxide radical: implications to neurodegenerative brain disorders. Chem. Res. Toxicol. 11:1998;639-650.
51. Yamamoto B., Pehek E. A neurochemical heterogeneity of the rat striatum as measured by in vivo electrochemistry and microdialysis. Brain Res. 506:1990;236-242.